Drug Profile
Research programme: drug repositioning and selection - Ore Pharmaceuticals/Solvay Pharmaeuticals
Latest Information Update: 01 Sep 2009
Price :
$50
*
At a glance
- Originator Solvay Pharmaceuticals
- Developer Ore Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 01 Sep 2009 No development reported - Preclinical for Undefined indication in USA (unspecified route)
- 29 Aug 2007 Preclinical trials in Undefined indication in USA (unspecified route)